Protagonist Therapeutics Inc expected to post a loss of 73 cents a share - Earnings Preview

Protagonist Therapeutics

28/04/2023 13:03

* Protagonist Therapeutics Inc  PTGX.OQ   PTGX.O  is
expected
to show a fall in quarterly revenue when it reports  results on
May 2 (estimated). 
    * The Newark California California-based  company is
expected to
report  a 92.2% decrease in revenue to $2 million from $25.72
million a year ago, according to the mean estimate from 5
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Protagonist
Therapeutics
Inc is for a loss of 73 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 0.5%
in the last three months. ​
    * Wall Street's median 12-month price target for Protagonist
Therapeutics Inc is $35​, above​ its last closing price
of $22.67. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2022  -0.52       -0.64      -0.69     Missed  -8.1
 Sep. 30 2022  -0.86       -0.87      -0.64     Beat    26.3
 Jun. 30 2022  -0.91       -0.93      -0.84     Beat    9.4​
 Mar. 31 2022  -0.58       -0.63      -0.43     Beat    31.6
 ​​Dec.        -0.81       -0.78      -0.77     Beat    1.6
 31 2021                                                
 Sep. 30 2021  -0.69       -0.67      -0.70     Missed  -4.5​
 Jun. 30 2021  -0.54       -0.55      -0.69     Missed  -26.1
 Mar. 31 2021  -0.56       -0.57      -0.54     Beat    4.9
 This summary was machine generated April 28 at 12:03 GMT.  All
figures in US dollars  unless otherwise stated